共 267 条
[1]
Robert C(2015)Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 2521-2532
[2]
Schachter J(2015)Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial Lancet Oncol 16 908-918
[3]
Long GV(2015)Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 23-34
[4]
Arance A(2015)Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med 372 2006-2017
[5]
Grob JJ(2017)Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma J Clin Oncol 35 785-792
[6]
Mortier L(2018)Immune-related adverse events associated with immune checkpoint blockade N Engl J Med 378 158-168
[7]
Ribas A(2017)Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials J Clin Oncol 35 3807-3814
[8]
Puzanov I(2019)Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis J Immunother Cancer 7 341-1047
[9]
Dummer R(2019)Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer JAMA Oncol 5 1043-1212
[10]
Schadendorf D(2015)Pembrolizumab cutaneous adverse events and their association with disease progression JAMA Dermatol 151 1206-51